GlassScriptPhysician profile
Harry Dounis
NPI 1124286083
$75,287.50
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,057 · 2021: $3,744 · 2022: $11K · 2023: $3,274 · 2024: $15K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Honoraria: $6,505 · Consulting Fee: $5,353 · Food and Beverage: $2,268 · Travel and Lodging: $349 · Education: $44.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,533.62 |
| Honoraria | $6,505.00 |
| Consulting Fee | $5,352.72 |
| Food and Beverage | $2,268.00 |
| Travel and Lodging | $348.66 |
| Education | $44.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $53,490.25 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $19,613.11 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $730.75 | 2019-2024 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $190.14 | 2019-2021 | |
| Ardelyx, INC. | $178.95 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $157.64 | 2021 | |
| Aurinia Pharma U.S., INC. | $157.17 | 2023-2025 | Lupkynis |
| Baxter Healthcare | $150.23 | 2023 | Renal - Chronic |
| Amgen INC. | $147.93 | 2022-2023 | Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $132.31 | 2023-2024 | Jesduvroq, Benlysta |
| Otsuka America Pharmaceutical, INC. | $114.39 | 2019 | |
| Travere Therapeutics, INC. | $59.99 | 2024 | |
| Vantive US Healthcare LLC | $56.25 | 2025 | Renal - Pd |
| Akebia Therapeutics INC | $38.21 | 2024 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $36.66 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.14 | 2023 | |
| Horizon Therapeutics Plc | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Dounis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.